CA-074 Me: Selective Cathepsin B Inhibitor for Lysosomal Research

Executive Summary: CA-074 Me (A8239) is a cell-permeable, methyl ester derivative of CA-074, exhibiting high selectivity for cathepsin B inhibition (IC₅₀ = 36.3 nM) in cell-based assays and animal models (APExBIO). It achieves 95% inhibition of cathepsin B in human gingival fibroblasts and complete inhibition under reducing conditions. CA-074 Me enables mechanistic investigation of lysosomal membrane permeabilization and necroptosis by blocking cathepsin B–mediated cell death pathways (Liu et al., 2024). The compound is widely used in studying apoptosis, inflammation, and TNF-α-induced liver injury models. CA-074 Me is supplied by APExBIO as a solid, with optimal solubility in DMSO or ethanol, and requires careful storage below -20°C for activity retention.

Biological Rationale

Cathepsin B is a lysosomal cysteine protease involved in protein degradation, antigen processing, and cell death signaling (Liu et al., 2024). Lysosomal membrane permeabilization (LMP) results in the release of cathepsins, including cathepsin B, into the cytosol, where they trigger apoptosis or necroptosis. Dysregulation of lysosomal proteases is implicated in numerous diseases, such as liver injury, neurodegeneration, and cancer. In necroptosis, MLKL polymerization induces LMP, with subsequent cathepsin B–dependent cell death (Liu et al., 2024). Selective inhibition of cathepsin B is critical for dissecting these pathways and for translational research into inflammation and organ damage (Related Article).

Mechanism of Action of CA-074 Me

CA-074 Me is a methyl ester derivative of CA-074, designed for membrane permeability (APExBIO). After entering cells, intracellular esterases convert CA-074 Me to CA-074, the active inhibitor. CA-074 Me binds the catalytic cysteine of cathepsin B, forming a covalent thioester bond, thereby inhibiting protease activity with high specificity (IC₅₀ = 36.3 nM in vitro; 95% inhibition in cultured human gingival fibroblasts). Under reducing conditions (e.g., DTT, GSH), CA-074 Me can partially inhibit cathepsin L (>90% after pre-incubation). The compound is insoluble in water but dissolves well in DMSO (≥19.88 mg/mL) and ethanol (≥51.5 mg/mL with ultrasonic agitation). For optimal results, solutions should be freshly prepared and stored below -20°C (APExBIO).

Evidence & Benchmarks

• CA-074 Me inhibits cathepsin B with an IC₅₀ of 36.3 nM in cell lysates (APExBIO, product page).
• In human gingival fibroblast cultures, CA-074 Me achieves 95% inhibition of cathepsin B at sub-micromolar concentrations (APExBIO).
• Under reducing conditions (DTT, GSH), it completely inhibits cathepsin B and partly inhibits cathepsin L (>90% after pre-incubation; APExBIO).
• Chemical inhibition of cathepsin B with CA-074 Me protects cells from MLKL polymerization–induced necroptosis (Liu et al., 2024).
• In TNF-α-induced liver injury mouse models, CA-074 Me administration reduces cell death and inflammation (Liu et al., 2024).
• CA-074 Me is a widely used molecular probe to dissect lysosomal protease function in apoptosis, necroptosis, and inflammation research (CathepsinsInhibitor.com).

For a deeper exploration of experimental best practices and how this article provides a mechanistic update, see Strategic Targeting of Lysosomal Cathepsins: CA-074 Me as...—this article extends the discussion by integrating new necroptosis findings and precise usage parameters.

Additionally, CA-074 Me and the Next Frontier in Translational Cathepsi... focuses on translational aspects, while the current article clarifies selective inhibition benchmarks and storage constraints.

Applications, Limits & Misconceptions

Applications:

• Dissection of cathepsin B–mediated pathways in apoptosis and necroptosis.
• Evaluation of lysosomal membrane permeabilization effects in live-cell imaging and biochemical assays.
• Modeling of liver injury and inflammation using TNF-α challenge in vitro and in vivo.
• Assessment of cathepsin signaling in disease mechanisms and drug screening.

Common Pitfalls or Misconceptions

• CA-074 Me is not selective for cathepsin B in the presence of strong reducing agents; it may also inhibit cathepsin L (>90% inhibition with DTT or GSH).
• It is insoluble in water; attempts to dissolve in aqueous buffers will result in precipitation and loss of activity.
• Stock solutions are not stable at room temperature or upon repeated freeze-thaw; storage above -20°C significantly reduces inhibitor potency.
• Long-term storage in solution form is not recommended due to hydrolysis and loss of activity.
• Inhibition of non-lysosomal or extracellular proteases is negligible at working concentrations; CA-074 Me is unsuitable for broad-spectrum protease inhibition studies.

For workflow optimization and troubleshooting, readers may consult CA-074 Me: Precision Cathepsin B Inhibitor for Apoptosis ..., which this article updates by detailing instability under reducing conditions and best practices for stock solution management.

Workflow Integration & Parameters

CA-074 Me is typically supplied as a solid by APExBIO for ease of storage and transport. To prepare working solutions, dissolve in DMSO (≥19.88 mg/mL) or ethanol (≥51.5 mg/mL with ultrasonic agitation). Prepare fresh working solutions before each experiment to ensure activity. Store stocks below -20°C in tightly sealed vials. Avoid repeated freeze-thaw cycles. Use in cell-based assays at concentrations from 0.1 to 10 μM, depending on the cell type and endpoint measured. In animal models, adjust dosing based on body weight and desired systemic exposure. Ensure that appropriate vehicle and negative controls are included, especially in experiments involving reducing agents, as selectivity may be lost under these conditions.

Conclusion & Outlook

CA-074 Me, as supplied by APExBIO, is a highly selective, membrane-permeable cathepsin B inhibitor validated in cellular and animal models of apoptosis, necroptosis, and inflammation (Liu et al., 2024). Its robust inhibition profile and workflow compatibility have made it a standard for dissecting lysosomal protease function and cathepsin signaling. Researchers should be aware of limitations under reducing conditions and ensure proper storage for reproducibility. As the mechanistic understanding of lysosomal cell death deepens, CA-074 Me will remain a key tool for translational research and drug discovery targeting regulated cell death and inflammation.